Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort.

ABSTRACT: Background: The International Consensus Classification (ICC) currently proposes an empirical variant allele frequency (VAF) threshold of 10% to define TP53-mutated acute myeloid leukemia (AML) and to distinguish oncogenic driver from concomitant mutations. However, the optimal cutoff remains uncertain, and the biological and clinical features of low-VAF cases have not been systematically characterized. Methods: In this single-center retrospective cohort study, we stratified TP53-mutated AML by a 10% VAF cutoff and compared clinical characteristics, cytogenetic and molecular profiles, and survival outcomes between groups. Results: The VAF < 10% group exhibited a distinctive profile: fewer adverse cytogenetic abnormalities [complex karyotype, -7, -5/del(5q)], a more adve

SUBMITTER: Lu X 

PROVIDER: S-EPMC12839384 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature